Fed. Circ. Won't Rethink Standing In Myriad Gene Patent Case
The Federal Circuit on Monday declined to reconsider the standing of the sole plaintiff in a suit challenging the validity of Myriad Genetics Inc.'s breast cancer gene patents, rejecting Myriad's argument...To view the full article, register now.
Already a subscriber? Click here to view full article